The clinical trial will test the effectiveness of Aposense's ML-10 molecular imaging system.
Aposense Ltd. (TASE: APOS) and its partner GlaxoSmithKline plc (NYSE; LSE: GSK) have obtained a permit from UK Medicines and Healthcare Products Regulatory Agency (MHRA) to undertake a clinical trial to test the effectiveness of Aposense's ML-10 molecular imaging system on patients with lymphoma.
Aposense and GSK are collaborating on applying the ML-10 system on new cancer drugs that GSK is developing.
Aposense seeks to apply apoptosis (programmed cell death) to develop personalized oncology, cardiology, and neurology treatments. Apoptosis is a critical factor in many diseases.
Aposense held its IPO last week. The share price rose 1.7% by early afternoon today to NIS 28.64, giving a market cap of NIS 755 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 14, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010